In short
China's 2024 asthma guideline updates the 2020 edition with a clearer diagnostic pathway, revised staging and severity grading, and 34 key recommendations on assessment, maintenance therapy, acute exacerbations, severe and atypical asthma.
What this guide covers: About the guideline · Diagnosis · Day-to-day management · Acute exacerbations · Practical points
About the guideline
The Chinese Thoracic Society's 2024 asthma guideline updates the 2020 edition with a clearer diagnostic pathway, revised clinical staging and severity grading, and refined recommendations on assessment, maintenance therapy, acute exacerbation management, severe asthma, atypical asthma, and management principles—34 key recommendations in total.
Diagnosis
Asthma is a common chronic airway disease. When symptoms suggest asthma but routine tests are inconclusive, a bronchial provocation test (if FEV1 ≥70% predicted) or a presumptive diagnostic pathway should be used rather than relying on a single cutoff.
Day-to-day management
Maintenance therapy is tailored to severity and control, with inhaled corticosteroids as the backbone. Regular assessment of control, triggers, and inhaler technique is central to keeping symptoms away.
Acute exacerbations
The guideline details how to recognize and manage flare-ups promptly to prevent progression. Severe asthma has dedicated assessment and treatment pathways.
Practical points
International patients with asthma should carry their inhaler and an action plan, keep a record of triggers, and confirm their controller regimen when consulting in China.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.


